{"DataElement":{"publicId":"3235002","version":"1","preferredName":"Next Therapy Post Surgery Radiation Therapy Administered Type","preferredDefinition":"a subdivision of the the subsequent action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process being given after surgery or radiation therapy.","longName":"3234992v1.0:3234993v1.0","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"3234992","version":"1","preferredName":"Next Therapy Post Surgery Radiation Therapy Administered","preferredDefinition":"information related to subsequent action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process being given after surgery or radiation therapy.","longName":"3234987v1.0:3234990v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"3234987","version":"1","preferredName":"Next Therapy","preferredDefinition":"Subsequent; immediately following in time or order.:An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C53286:C15368","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Next","conceptCode":"C53286","definition":"Subsequent; immediately following in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapy","conceptCode":"C15368","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A31A51D8-4F36-5ABC-E040-BB89AD436836","latestVersionIndicator":"Yes","beginDate":"2011-05-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-05-12","modifiedBy":"ONEDATA","dateModified":"2011-05-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3234990","version":"1","preferredName":"Post Surgery Radiation Therapy Administered","preferredDefinition":"Post; occuring after.:A specialty in which manual or operative procedures are used in the treatment of disease, injuries, or deformities.:use PHOTOTHERAPY, LASER THERAPY, or ULTRAVIOLET THERAPY for therapeutic radiation with visible, laser, or ultraviolet light, respectively.:Given.","longName":"C38008:C17173:C15313:C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Post","conceptCode":"C38008","definition":"Happening at a time subsequent to a reference time; later in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Surgery","conceptCode":"C17173","definition":"The branch of medical science that treats disease or injury by operative procedures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Radiation Therapy","conceptCode":"C15313","definition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A31A51D8-4F5B-5ABC-E040-BB89AD436836","latestVersionIndicator":"Yes","beginDate":"2011-05-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-05-12","modifiedBy":"ONEDATA","dateModified":"2011-05-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCCTG CRF:North Central Cancer Treatment Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A31A51D8-4F6C-5ABC-E040-BB89AD436836","latestVersionIndicator":"Yes","beginDate":"2011-05-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-05-12","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3234993","version":"1","preferredName":"Next Therapy Administered Type","preferredDefinition":"a subdivision of the subsequent therapy being given.","longName":"3234993v1.0","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"35","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other Therapy","valueDescription":"OTHER THERAPY","ValueMeaning":{"publicId":"2563822","version":"1","preferredName":"OTHER THERAPY","longName":"2563822","preferredDefinition":"OTHER THERAPY","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other Therapy","conceptCode":"C15645","definition":"Definition not available.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C65B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-12-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-23","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A31A92C2-34CB-2449-E040-BB89AD4336BB","beginDate":"2011-05-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-05-12","modifiedBy":"ONEDATA","dateModified":"2011-05-12","deletedIndicator":"No"},{"value":"Other Biologic/targeted therapy","valueDescription":"Other Biologic/targeted therapy","ValueMeaning":{"publicId":"3234994","version":"1","preferredName":"Other Biologic/targeted therapy","longName":"3234994","preferredDefinition":"Other Biologic/targeted therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A31A92C2-34D5-2449-E040-BB89AD4336BB","latestVersionIndicator":"Yes","beginDate":"2011-05-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-05-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A31A92C2-34EE-2449-E040-BB89AD4336BB","beginDate":"2011-05-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-05-12","modifiedBy":"ONEDATA","dateModified":"2011-05-12","deletedIndicator":"No"},{"value":"Other anti-angiogenesis therapy","valueDescription":"Other anti-angiogenesis therapy","ValueMeaning":{"publicId":"3234995","version":"1","preferredName":"Other anti-angiogenesis therapy","longName":"3234995","preferredDefinition":"Other anti-angiogenesis therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A31A92C2-34F8-2449-E040-BB89AD4336BB","latestVersionIndicator":"Yes","beginDate":"2011-05-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-05-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A31A92C2-3511-2449-E040-BB89AD4336BB","beginDate":"2011-05-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-05-12","modifiedBy":"ONEDATA","dateModified":"2011-05-12","deletedIndicator":"No"},{"value":"Other Chemotherapy Regimens","valueDescription":"Other Chemotherapy Regimens","ValueMeaning":{"publicId":"3234996","version":"1","preferredName":"Other Chemotherapy Regimens","longName":"3234996","preferredDefinition":"Other Chemotherapy Regimens","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A31A92C2-351B-2449-E040-BB89AD4336BB","latestVersionIndicator":"Yes","beginDate":"2011-05-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-05-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A31A92C2-3534-2449-E040-BB89AD4336BB","beginDate":"2011-05-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-05-12","modifiedBy":"ONEDATA","dateModified":"2011-05-12","deletedIndicator":"No"},{"value":"Other EGFR inhibitor","valueDescription":"Other EGFR inhibitor","ValueMeaning":{"publicId":"3234997","version":"1","preferredName":"Other EGFR inhibitor","longName":"3234997","preferredDefinition":"Other EGFR inhibitor","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A31A92C2-353E-2449-E040-BB89AD4336BB","latestVersionIndicator":"Yes","beginDate":"2011-05-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-05-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A31A92C2-3557-2449-E040-BB89AD4336BB","beginDate":"2011-05-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-05-12","modifiedBy":"ONEDATA","dateModified":"2011-05-12","deletedIndicator":"No"},{"value":"Cetuximab with other agents","valueDescription":"Cetuximab with other agents","ValueMeaning":{"publicId":"3234998","version":"1","preferredName":"Cetuximab with other agents","longName":"3234998","preferredDefinition":"Cetuximab with other agents","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A31A92C2-3561-2449-E040-BB89AD4336BB","latestVersionIndicator":"Yes","beginDate":"2011-05-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-05-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A31A92C2-357A-2449-E040-BB89AD4336BB","beginDate":"2011-05-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-05-12","modifiedBy":"ONEDATA","dateModified":"2011-05-12","deletedIndicator":"No"},{"value":"Cetuximab alone","valueDescription":"Cetuximab alone","ValueMeaning":{"publicId":"3234999","version":"1","preferredName":"Cetuximab alone","longName":"3234999","preferredDefinition":"Cetuximab alone","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A31A92C2-3584-2449-E040-BB89AD4336BB","latestVersionIndicator":"Yes","beginDate":"2011-05-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-05-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A31A92C2-359D-2449-E040-BB89AD4336BB","beginDate":"2011-05-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-05-12","modifiedBy":"ONEDATA","dateModified":"2011-05-12","deletedIndicator":"No"},{"value":"Platinum-based Chemotherapy","valueDescription":"Platinum-based Chemotherapy","ValueMeaning":{"publicId":"2580754","version":"1","preferredName":"Platinum-based Chemotherapy","longName":"2580754","preferredDefinition":"The use of synthetic or naturally-occurring inorganic compounds which contain platinum as the central atom for the treatment of diseases.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-087F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-06","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-09-06","modifiedBy":"CAMPBELB","dateModified":"2006-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A31A92C2-35A7-2449-E040-BB89AD4336BB","beginDate":"2011-05-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-05-12","modifiedBy":"ONEDATA","dateModified":"2011-05-12","deletedIndicator":"No"},{"value":"None","valueDescription":"None","ValueMeaning":{"publicId":"2577064","version":"1","preferredName":"None","longName":"2577064","preferredDefinition":"No person or thing, nobody, not any.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"None","conceptCode":"C41132","definition":"No person or thing, nobody, not any.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FA15-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-22","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-22","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A31A92C2-35B1-2449-E040-BB89AD4336BB","beginDate":"2011-05-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-05-12","modifiedBy":"ONEDATA","dateModified":"2011-05-12","deletedIndicator":"No"},{"value":"Surgery","valueDescription":"Surgery","ValueMeaning":{"publicId":"2570738","version":"1","preferredName":"Surgery","longName":"2570738","preferredDefinition":"Surgery","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E15F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-06-21","endDate":null,"createdBy":"SBR","dateCreated":"2004-06-21","modifiedBy":"CLOHNES","dateModified":"2022-11-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A31A92C2-35BB-2449-E040-BB89AD4336BB","beginDate":"2011-05-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-05-12","modifiedBy":"ONEDATA","dateModified":"2011-05-12","deletedIndicator":"No"},{"value":"RT","valueDescription":"Radiation Therapy","ValueMeaning":{"publicId":"3235000","version":"1","preferredName":"Radiation Therapy","longName":"3235000","preferredDefinition":"use PHOTOTHERAPY, LASER THERAPY, or ULTRAVIOLET THERAPY for therapeutic radiation with visible, laser, or ultraviolet light, respectively.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Radiation Therapy","conceptCode":"C15313","definition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A31A92C2-35C6-2449-E040-BB89AD4336BB","latestVersionIndicator":"Yes","beginDate":"2011-05-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-05-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A31A92C2-35DE-2449-E040-BB89AD4336BB","beginDate":"2011-05-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-05-12","modifiedBy":"ONEDATA","dateModified":"2011-05-12","deletedIndicator":"No"},{"value":"Bevacizumab","valueDescription":"Bevacizumab","ValueMeaning":{"publicId":"2574306","version":"1","preferredName":"Bevacizumab","longName":"2574306","preferredDefinition":"A monoclonal antibody that may prevent the growth of blood vessels from surrounding tissue to a solid tumor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bevacizumab","conceptCode":"C2039","definition":"A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine.  Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EF4F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-02","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-04-02","modifiedBy":"ALAIS","dateModified":"2006-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A31A92C2-35E9-2449-E040-BB89AD4336BB","beginDate":"2011-05-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-05-12","modifiedBy":"ONEDATA","dateModified":"2011-05-12","deletedIndicator":"No"},{"value":"Treatment Week 6","valueDescription":"Treat Week Six","ValueMeaning":{"publicId":"5370954","version":"1","preferredName":"Treat Week Six","longName":"5370954","preferredDefinition":"Subject to a process with the aim of readying for some purpose, improving, or remedying a condition.: Any period of seven consecutive days.: A natural number greater than 5 and less than 7 and the quantity that it denotes: the sum of five and one.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Treat","conceptCode":"C70742","definition":"Subject to a process with the aim of readying for some purpose, improving, or remedying a condition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Week","conceptCode":"C29844","definition":"Any period of seven consecutive days.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Six","conceptCode":"C66837","definition":"A natural number greater than 5 and less than 7 and the quantity that it denotes: the sum of five and one.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"392A911E-E3F9-425D-E050-BB89AD43316A","latestVersionIndicator":"Yes","beginDate":"2016-08-03","endDate":null,"createdBy":"MORENOC","dateCreated":"2016-08-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"392A911E-E412-425D-E050-BB89AD43316A","beginDate":"2016-08-03","endDate":null,"createdBy":"MORENOC","dateCreated":"2016-08-03","modifiedBy":"ONEDATA","dateModified":"2016-08-03","deletedIndicator":"No"},{"value":"Treatment Week 12","valueDescription":"Treat Week Twelve","ValueMeaning":{"publicId":"5370952","version":"1","preferredName":"Treat Week Twelve","longName":"5370952","preferredDefinition":"Subject to a process with the aim of readying for some purpose, improving, or remedying a condition.: Any period of seven consecutive days.: A natural number greater than 11 and less than 13 and the quantity that it denotes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Treat","conceptCode":"C70742","definition":"Subject to a process with the aim of readying for some purpose, improving, or remedying a condition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Week","conceptCode":"C29844","definition":"Any period of seven consecutive days.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Twelve","conceptCode":"C113426","definition":"A natural number greater than 11 and less than 13 and the quantity that it denotes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"392BC52F-BE65-8D3B-E050-BB89AD4327AC","latestVersionIndicator":"Yes","beginDate":"2016-08-03","endDate":null,"createdBy":"MORENOC","dateCreated":"2016-08-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"392BC52F-BE7E-8D3B-E050-BB89AD4327AC","beginDate":"2016-08-03","endDate":null,"createdBy":"MORENOC","dateCreated":"2016-08-03","modifiedBy":"ONEDATA","dateModified":"2016-08-03","deletedIndicator":"No"},{"value":"No Treatment","valueDescription":"No Treat","ValueMeaning":{"publicId":"3104040","version":"1","preferredName":"No Treat","longName":"3104040","preferredDefinition":"The non-affirmative response to a question.: Subject to a process with the aim of readying for some purpose, improving, or remedying a condition.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treat","conceptCode":"C70742","definition":"Subject to a process with the aim of readying for some purpose, improving, or remedying a condition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87ABD1F4-DEAF-7475-E040-BB89AD4333B5","latestVersionIndicator":"Yes","beginDate":"2010-05-28","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-05-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"392BC52F-BEBC-8D3B-E050-BB89AD4327AC","beginDate":"2016-08-03","endDate":null,"createdBy":"MORENOC","dateCreated":"2016-08-03","modifiedBy":"ONEDATA","dateModified":"2016-08-03","deletedIndicator":"No"},{"value":"Entrectinib","valueDescription":"Entrectinib","ValueMeaning":{"publicId":"6617876","version":"1","preferredName":"Entrectinib","longName":"6617876","preferredDefinition":"An orally bioavailable inhibitor of the tyrosine kinases tropomyosin receptor kinases (Trk) A, B and C, C-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK), with potential antineoplastic activity. Upon administration, entrectinib binds to and inhibits TrkA, TrkB, TrkC, ROS1 and ALK. Inhibition of these kinases may result in a disruption of TrkA-, TrkB-, TrkC-, ROS1-, and ALK-mediated signaling. This leads to an induction of apoptosis and an inhibition of tumor cell proliferation in tumor cells that express these kinases. TrkA, TrkB, TrkC, ROS1 and ALK are overexpressed in a variety of cancer cell types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Entrectinib","conceptCode":"C114984","definition":"An orally bioavailable inhibitor of the tyrosine kinases tropomyosin receptor kinases (Trk) A, B and C, C-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK), with potential antineoplastic activity. Upon administration, entrectinib binds to and inhibits TrkA, TrkB, TrkC, ROS1 and ALK. Inhibition of these kinases may result in a disruption of TrkA-, TrkB-, TrkC-, ROS1-, and ALK-mediated signaling. This leads to an induction of apoptosis and an inhibition of tumor cell proliferation in tumor cells that express these kinases. TrkA, TrkB, TrkC, ROS1 and ALK are overexpressed in a variety of cancer cell types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"800F9D7B-55F3-37F4-E053-F662850ADFFC","latestVersionIndicator":"Yes","beginDate":"2019-01-22","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-01-22","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"80105F9B-B53C-1A7A-E053-F662850A6659","beginDate":"2019-01-22","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-01-22","modifiedBy":"ONEDATA","dateModified":"2019-01-22","deletedIndicator":"No"},{"value":"GDC-0084","valueDescription":"PI3K Inhibitor GDC-0084","ValueMeaning":{"publicId":"6617877","version":"1","preferredName":"PI3K Inhibitor GDC-0084","longName":"6617877","preferredDefinition":"A phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. PI3K inhibitor GDC-0084 specifically inhibits PI3K in the PI3K/AKT kinase (or protein kinase B) signaling pathway, thereby inhibiting the activation of the PI3K signaling pathway. This may result in the inhibition of both cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Paxalisib","conceptCode":"C116877","definition":"A phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. paxalisib specifically inhibits PI3K in the PI3K/AKT kinase (or protein kinase B) signaling pathway, thereby inhibiting the activation of the PI3K signaling pathway. This may result in the inhibition of both cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"800F9D7B-5618-37F4-E053-F662850ADFFC","latestVersionIndicator":"Yes","beginDate":"2019-01-22","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-01-22","modifiedBy":"ONEDATA","dateModified":"2019-01-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"80105F9B-B546-1A7A-E053-F662850A6659","beginDate":"2019-01-22","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-01-22","modifiedBy":"ONEDATA","dateModified":"2019-01-22","deletedIndicator":"No"},{"value":"Abemaciclib","valueDescription":"Abemaciclib","ValueMeaning":{"publicId":"6148605","version":"1","preferredName":"Abemaciclib","longName":"6148605","preferredDefinition":"An orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. Abemaciclib specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early G1. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of the serine/threonine kinases CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Abemaciclib","conceptCode":"C97660","definition":"An orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. Abemaciclib specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early G1. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of the serine/threonine kinases CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"682DF2C6-77AE-47D7-E053-F662850A61D2","latestVersionIndicator":"Yes","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"80105F9B-B550-1A7A-E053-F662850A6659","beginDate":"2019-01-22","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-01-22","modifiedBy":"ONEDATA","dateModified":"2019-01-22","deletedIndicator":"No"},{"value":"Off Study","valueDescription":"Off Study","ValueMeaning":{"publicId":"6618079","version":"1","preferredName":"Off Study","longName":"6618079","preferredDefinition":"No longer participating in a study; not being followed and will not be retreated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Off Study","conceptCode":"C29851","definition":"No longer participating in a study; not being followed and will not be retreated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"801EA03E-939A-7862-E053-F662850A4F83","latestVersionIndicator":"Yes","beginDate":"2019-01-23","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-01-23","modifiedBy":"ONEDATA","dateModified":"2019-01-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"801EA03E-93B2-7862-E053-F662850A4F83","beginDate":"2019-01-23","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-01-23","modifiedBy":"ONEDATA","dateModified":"2019-01-23","deletedIndicator":"No"},{"value":"Follow-Up (Week 12)","valueDescription":"Follow-up Week Twelve","ValueMeaning":{"publicId":"6618080","version":"1","preferredName":"Follow-up Week Twelve","longName":"6618080","preferredDefinition":"The process by which information about the health status of an individual is obtained after a study has officially closed; an activity that continues something that has already begun or that repeats something that has already been done.: Any period of seven consecutive days.: A natural number greater than 11 and less than 13 and the quantity that it denotes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Follow-Up","conceptCode":"C16033","definition":"The process by which information about the health status of an individual is obtained after a study has officially closed; an activity that continues something that has already begun or that repeats something that has already been done.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Week","conceptCode":"C29844","definition":"Any period of seven consecutive days.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Twelve","conceptCode":"C113426","definition":"A natural number greater than 11 and less than 13 and the quantity that it denotes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"801FA6E7-A5DC-74E7-E053-F662850AFF49","latestVersionIndicator":"Yes","beginDate":"2019-01-23","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-01-23","modifiedBy":"ONEDATA","dateModified":"2019-01-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"801FA6E7-A5F5-74E7-E053-F662850AFF49","beginDate":"2019-01-23","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-01-23","modifiedBy":"ONEDATA","dateModified":"2019-01-23","deletedIndicator":"No"},{"value":"Follow-Up (Week 8)","valueDescription":"Follow-up Week Eight","ValueMeaning":{"publicId":"6618081","version":"1","preferredName":"Follow-up Week Eight","longName":"6618081","preferredDefinition":"The process by which information about the health status of an individual is obtained after a study has officially closed; an activity that continues something that has already begun or that repeats something that has already been done.: Any period of seven consecutive days.: A natural number greater than 7 and less than 9 and the quantity that it denotes: the sum of seven and one.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Follow-Up","conceptCode":"C16033","definition":"The process by which information about the health status of an individual is obtained after a study has officially closed; an activity that continues something that has already begun or that repeats something that has already been done.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Week","conceptCode":"C29844","definition":"Any period of seven consecutive days.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Eight","conceptCode":"C66839","definition":"A natural number greater than 7 and less than 9 and the quantity that it denotes: the sum of seven and one.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"801FA6E7-A603-74E7-E053-F662850AFF49","latestVersionIndicator":"Yes","beginDate":"2019-01-23","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-01-23","modifiedBy":"ONEDATA","dateModified":"2019-01-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"801FA6E7-A61C-74E7-E053-F662850AFF49","beginDate":"2019-01-23","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-01-23","modifiedBy":"ONEDATA","dateModified":"2019-01-23","deletedIndicator":"No"},{"value":"Induction Therapy","valueDescription":"Induction Therapy","ValueMeaning":{"publicId":"6859325","version":"1","preferredName":"Induction Therapy","longName":"6859325","preferredDefinition":"The first choice of treatment for a particular type of cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Induction Therapy","conceptCode":"C158876","definition":"The first choice of treatment for a particular type of cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"90A8573C-3838-34AF-E053-F662850A7E27","latestVersionIndicator":"Yes","beginDate":"2019-08-22","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-08-22","modifiedBy":"GDEEN","dateModified":"2023-07-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"90A8573C-3851-34AF-E053-F662850A7E27","beginDate":"2019-08-22","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-08-22","modifiedBy":"ONEDATA","dateModified":"2019-08-22","deletedIndicator":"No"},{"value":"Maintenance Therapy","valueDescription":"Maintenance Therapy","ValueMeaning":{"publicId":"3828964","version":"1","preferredName":"Maintenance Therapy","longName":"3828964","preferredDefinition":"Continuation of treatment for an extended period of time to prevent relapse.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Maintenance Therapy","conceptCode":"C15688","definition":"Continuation of treatment for an extended period of time to prevent relapse.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E2A8BB67-2BF1-B6D0-E040-BB89AD43093C","latestVersionIndicator":"Yes","beginDate":"2013-07-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-07-29","modifiedBy":"GDEEN","dateModified":"2023-07-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"91074CED-139B-1832-E053-F662850AD97A","beginDate":"2019-08-26","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-08-26","modifiedBy":"ONEDATA","dateModified":"2019-08-26","deletedIndicator":"No"},{"value":"Oxaliplatin + Duloxetine/Placebo","valueDescription":"Placebo Duloxetine Oxaliplatin","ValueMeaning":{"publicId":"7062621","version":"1","preferredName":"Placebo Duloxetine Oxaliplatin","longName":"7062621","preferredDefinition":"An inactive substance, treatment or procedure that is intended to provide baseline measurements for the experimental protocol of a clinical trial.: A drug used to treat depression and peripheral neuropathy (pain, numbness, tingling, burning, or weakness in the hands or feet) that can occur with diabetes. It is also being studied in the treatment of peripheral neuropathy caused by certain anticancer drugs. Cymbalta increases the amount of certain chemicals in the brain that help relieve depression and pain. It is a type of serotonin and norepinephrine reuptake inhibitor.: An organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and with an oxalate ligand as a 'leaving group.' A 'leaving group' is an atom or a group of atoms that is displaced as a stable species taking with it the bonding electrons. After displacement of the labile oxalate ligand leaving group, active oxaliplatin derivatives, such as monoaquo and diaquo DACH platinum, alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity. The DACH side chain appears to inhibit alkylating-agent resistance. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Placebo","conceptCode":"C753","definition":"An inactive substance, treatment or procedure that is intended to provide baseline measurements for the experimental protocol of a clinical trial.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Duloxetine","conceptCode":"C65495","definition":"A drug used to treat depression and peripheral neuropathy (pain, numbness, tingling, burning, or weakness in the hands or feet) that can occur with diabetes. It is also being studied in the treatment of peripheral neuropathy caused by certain anticancer drugs. Cymbalta increases the amount of certain chemicals in the brain that help relieve depression and pain. It is a type of serotonin and norepinephrine reuptake inhibitor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Oxaliplatin","conceptCode":"C1181","definition":"An organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and with an oxalate ligand as a 'leaving group.' A 'leaving group' is an atom or a group of atoms that is displaced as a stable species taking with it the bonding electrons. After displacement of the labile oxalate ligand leaving group, active oxaliplatin derivatives, such as monoaquo and diaquo DACH platinum, alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity. The DACH side chain appears to inhibit alkylating-agent resistance. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97B85FBA-6E34-268D-E053-F662850A62BF","latestVersionIndicator":"Yes","beginDate":"2019-11-19","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-11-19","modifiedBy":"ONEDATA","dateModified":"2019-11-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97B85FBA-6E4D-268D-E053-F662850A62BF","beginDate":"2019-11-19","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-11-19","modifiedBy":"ONEDATA","dateModified":"2019-11-19","deletedIndicator":"No"},{"value":"Duloxetine/Placebo Only","valueDescription":"Placebo Duloxetine","ValueMeaning":{"publicId":"7060612","version":"1","preferredName":"Placebo Duloxetine","longName":"7060612","preferredDefinition":"An inactive substance, treatment or procedure that is intended to provide baseline measurements for the experimental protocol of a clinical trial.: A drug used to treat depression and peripheral neuropathy (pain, numbness, tingling, burning, or weakness in the hands or feet) that can occur with diabetes. It is also being studied in the treatment of peripheral neuropathy caused by certain anticancer drugs. Cymbalta increases the amount of certain chemicals in the brain that help relieve depression and pain. It is a type of serotonin and norepinephrine reuptake inhibitor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Placebo","conceptCode":"C753","definition":"An inactive substance, treatment or procedure that is intended to provide baseline measurements for the experimental protocol of a clinical trial.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Duloxetine","conceptCode":"C65495","definition":"A drug used to treat depression and peripheral neuropathy (pain, numbness, tingling, burning, or weakness in the hands or feet) that can occur with diabetes. It is also being studied in the treatment of peripheral neuropathy caused by certain anticancer drugs. Cymbalta increases the amount of certain chemicals in the brain that help relieve depression and pain. It is a type of serotonin and norepinephrine reuptake inhibitor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97A01C77-D281-5625-E053-F662850A4466","latestVersionIndicator":"Yes","beginDate":"2019-11-19","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-11-19","modifiedBy":"ONEDATA","dateModified":"2019-11-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A01C77-D29A-5625-E053-F662850A4466","beginDate":"2019-11-19","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-11-19","modifiedBy":"ONEDATA","dateModified":"2019-11-19","deletedIndicator":"No"},{"value":"Course IV","valueDescription":"Course IV","ValueMeaning":{"publicId":"7245858","version":"1","preferredName":"Course IV","longName":"7245858","preferredDefinition":"Course IV","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A33E21D5-169B-4514-E053-F662850A7220","latestVersionIndicator":"Yes","beginDate":"2020-04-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-04-14","modifiedBy":"ONEDATA","dateModified":"2020-04-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A33E21D5-16B4-4514-E053-F662850A7220","beginDate":"2020-04-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-04-14","modifiedBy":"ONEDATA","dateModified":"2020-04-14","deletedIndicator":"No"},{"value":"Course V","valueDescription":"Course V","ValueMeaning":{"publicId":"7245857","version":"1","preferredName":"Course V","longName":"7245857","preferredDefinition":"Course V","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A33E21D5-1678-4514-E053-F662850A7220","latestVersionIndicator":"Yes","beginDate":"2020-04-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-04-14","modifiedBy":"ONEDATA","dateModified":"2020-04-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A33E21D5-1691-4514-E053-F662850A7220","beginDate":"2020-04-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-04-14","modifiedBy":"ONEDATA","dateModified":"2020-04-14","deletedIndicator":"No"},{"value":"Course III","valueDescription":"Course III","ValueMeaning":{"publicId":"7245859","version":"1","preferredName":"Course III","longName":"7245859","preferredDefinition":"Course III","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A33E21D5-16BE-4514-E053-F662850A7220","latestVersionIndicator":"Yes","beginDate":"2020-04-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-04-14","modifiedBy":"ONEDATA","dateModified":"2020-04-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A33E21D5-16D7-4514-E053-F662850A7220","beginDate":"2020-04-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-04-14","modifiedBy":"ONEDATA","dateModified":"2020-04-14","deletedIndicator":"No"},{"value":"Course II","valueDescription":"Course II","ValueMeaning":{"publicId":"7245860","version":"1","preferredName":"Course II","longName":"7245860","preferredDefinition":"Course II","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A33E21D5-16E1-4514-E053-F662850A7220","latestVersionIndicator":"Yes","beginDate":"2020-04-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-04-14","modifiedBy":"ONEDATA","dateModified":"2020-04-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A33E21D5-16FA-4514-E053-F662850A7220","beginDate":"2020-04-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-04-14","modifiedBy":"ONEDATA","dateModified":"2020-04-14","deletedIndicator":"No"},{"value":"Course I","valueDescription":"Course I","ValueMeaning":{"publicId":"7245861","version":"1","preferredName":"Course I","longName":"7245861","preferredDefinition":"Course I","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A33E21D5-1704-4514-E053-F662850A7220","latestVersionIndicator":"Yes","beginDate":"2020-04-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-04-14","modifiedBy":"ONEDATA","dateModified":"2020-04-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A33E21D5-171D-4514-E053-F662850A7220","beginDate":"2020-04-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-04-14","modifiedBy":"ONEDATA","dateModified":"2020-04-14","deletedIndicator":"No"},{"value":"Inotuzumab","valueDescription":"Inotuzumab Ozogamicin","ValueMeaning":{"publicId":"5577157","version":"1","preferredName":"Inotuzumab Ozogamicin","longName":"5577157","preferredDefinition":"A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inotuzumab Ozogamicin","conceptCode":"C71542","definition":"A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"415CA911-09D6-28BD-E053-F662850AAA2B","latestVersionIndicator":"Yes","beginDate":"2016-11-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2016-11-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A33E21D5-1727-4514-E053-F662850A7220","beginDate":"2020-04-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-04-14","modifiedBy":"ONEDATA","dateModified":"2020-04-14","deletedIndicator":"No"},{"value":"Blinatumomab","valueDescription":"Blinatumomab","ValueMeaning":{"publicId":"3690103","version":"1","preferredName":"Blinatumomab","longName":"3690103","preferredDefinition":"A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Blinatumomab","conceptCode":"C62528","definition":"A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D68C2697-3E36-5AFE-E040-BB89AD431E18","latestVersionIndicator":"Yes","beginDate":"2013-02-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-02-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A33E21D5-1731-4514-E053-F662850A7220","beginDate":"2020-04-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-04-14","modifiedBy":"ONEDATA","dateModified":"2020-04-14","deletedIndicator":"No"},{"value":"Off study due to invasive contralateral breast disease or positive margins (Arm 1 and Arm 2 patients) or  <  8 LNs  removed (Arm 1 patients only)","valueDescription":"Off study due to invasive contralateral breast disease or positive margins (Arm 1 and Arm 2 patients) or  <  8 LNs  removed (Arm 1 patients only)","ValueMeaning":{"publicId":"7187224","version":"1","preferredName":"Off study due to invasive contralateral breast disease or positive margins (Arm 1 and Arm 2 patients) or  <  8 LNs  removed (Arm 1 patients only)","longName":"7187224","preferredDefinition":"Off study due to invasive contralateral breast disease or positive margins (Arm 1 and Arm 2 patients) or  <  8 LNs  removed (Arm 1 patients only)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9FF4D3CB-F9C0-5F21-E053-F662850AE2FF","latestVersionIndicator":"Yes","beginDate":"2020-03-03","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-03-03","modifiedBy":"ONEDATA","dateModified":"2020-03-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9FF4D3CB-F9D9-5F21-E053-F662850AE2FF","beginDate":"2020-03-03","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-03-03","modifiedBy":"ONEDATA","dateModified":"2020-03-03","deletedIndicator":"No"},{"value":"Off study due to having more than 8 lymph nodes removed at SLN surgery (SLN Surgery Only) by final pathology","valueDescription":"Off study due to having more than 8 lymph nodes removed at SLN surgery (SLN Surgery Only) by final pathology","ValueMeaning":{"publicId":"7187225","version":"1","preferredName":"Off study due to having more than 8 lymph nodes removed at SLN surgery (SLN Surgery Only) by final pathology","longName":"7187225","preferredDefinition":"Off study due to having more than 8 lymph nodes removed at SLN surgery (SLN Surgery Only) by final pathology","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9FF4D3CB-F9E3-5F21-E053-F662850AE2FF","latestVersionIndicator":"Yes","beginDate":"2020-03-03","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-03-03","modifiedBy":"ONEDATA","dateModified":"2020-03-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9FF4D3CB-F9FC-5F21-E053-F662850AE2FF","beginDate":"2020-03-03","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-03-03","modifiedBy":"ONEDATA","dateModified":"2020-03-03","deletedIndicator":"No"},{"value":"Off study due to final pathology showing isolated tumor cells or node negative disease","valueDescription":"Off study due to final pathology showing isolated tumor cells or node negative disease","ValueMeaning":{"publicId":"7187226","version":"1","preferredName":"Off study due to final pathology showing isolated tumor cells or node negative disease","longName":"7187226","preferredDefinition":"Off study due to final pathology showing isolated tumor cells or node negative disease","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9FF4D3CB-FA06-5F21-E053-F662850AE2FF","latestVersionIndicator":"Yes","beginDate":"2020-03-03","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-03-03","modifiedBy":"ONEDATA","dateModified":"2020-03-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9FF4D3CB-FA1F-5F21-E053-F662850AE2FF","beginDate":"2020-03-03","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-03-03","modifiedBy":"ONEDATA","dateModified":"2020-03-03","deletedIndicator":"No"},{"value":"Open-Label Therapy (Cabozantinib)","valueDescription":"Open-Label Therapy (Cabozantinib)","ValueMeaning":{"publicId":"7405814","version":"1","preferredName":"Open-Label Therapy (Cabozantinib)","longName":"7405814","preferredDefinition":"Open-Label Therapy (Cabozantinib)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD526FB0-6CF4-17B4-E053-4EBD850A7A34","latestVersionIndicator":"Yes","beginDate":"2020-08-20","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-08-20","modifiedBy":"ONEDATA","dateModified":"2020-08-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AD526FB0-6D0D-17B4-E053-4EBD850A7A34","beginDate":"2020-08-20","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-08-20","modifiedBy":"ONEDATA","dateModified":"2020-08-20","deletedIndicator":"No"},{"value":"Initial Crossover to Open-Label Therapy (Cabozantinib)","valueDescription":"Initial Crossover to Open-Label Therapy (Cabozantinib)","ValueMeaning":{"publicId":"7405815","version":"1","preferredName":"Initial Crossover to Open-Label Therapy (Cabozantinib)","longName":"7405815","preferredDefinition":"Initial Crossover to Open-Label Therapy (Cabozantinib)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD526FB0-6D17-17B4-E053-4EBD850A7A34","latestVersionIndicator":"Yes","beginDate":"2020-08-20","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-08-20","modifiedBy":"ONEDATA","dateModified":"2020-08-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AD526FB0-6D30-17B4-E053-4EBD850A7A34","beginDate":"2020-08-20","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-08-20","modifiedBy":"ONEDATA","dateModified":"2020-08-20","deletedIndicator":"No"},{"value":"Treatment Observation","valueDescription":"Treatment Observation","ValueMeaning":{"publicId":"7405816","version":"1","preferredName":"Treatment Observation","longName":"7405816","preferredDefinition":"Treatment Observation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD526FB0-6D3A-17B4-E053-4EBD850A7A34","latestVersionIndicator":"Yes","beginDate":"2020-08-20","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-08-20","modifiedBy":"ONEDATA","dateModified":"2020-08-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AD526FB0-6D53-17B4-E053-4EBD850A7A34","beginDate":"2020-08-20","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-08-20","modifiedBy":"ONEDATA","dateModified":"2020-08-20","deletedIndicator":"No"},{"value":"Continue on Blinded Therapy (Cabozantinib/Placebo)","valueDescription":"Continue on Blinded Therapy (Cabozantinib/Placebo)","ValueMeaning":{"publicId":"7405817","version":"1","preferredName":"Continue on Blinded Therapy (Cabozantinib/Placebo)","longName":"7405817","preferredDefinition":"Continue on Blinded Therapy (Cabozantinib/Placebo)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD526FB0-6D5D-17B4-E053-4EBD850A7A34","latestVersionIndicator":"Yes","beginDate":"2020-08-20","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-08-20","modifiedBy":"ONEDATA","dateModified":"2020-08-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AD526FB0-6D76-17B4-E053-4EBD850A7A34","beginDate":"2020-08-20","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-08-20","modifiedBy":"ONEDATA","dateModified":"2020-08-20","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCCTG CRF:North Central Cancer Treatment Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A31A92C2-34B5-2449-E040-BB89AD4336BB","latestVersionIndicator":"Yes","beginDate":"2011-05-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-05-12","modifiedBy":"CAMPBELB","dateModified":"2020-08-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"After surgery or radiation, w","type":"Preferred Question Text","description":"After surgery or radiation, what is the first systemic cancer therapy planned for this patient","url":null,"context":"CTEP"}],"origin":"NCCTG CRF:North Central Cancer Treatment Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A31A92C2-3613-2449-E040-BB89AD4336BB","latestVersionIndicator":"Yes","beginDate":"2011-05-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-05-12","modifiedBy":"ALAIS","dateModified":"2011-10-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}